OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. The company headquarter is located in United States. The company was established in the 2018.

TickerOKUR
Long NameOnKure Therapeutics Inc. Class A Common Stock
Short NameOnKure Therapeutics Class A